Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor

• Over 90% of granulosa cell tumors have a FOXL2 mutation that contributes to aromatase upregulation. • Chemotherapy has demonstrated limited efficacy in the treatment of granulosa cell tumors. • A patient with recurrent granulosa cell tumor responded briefly to anastrazole treatment. • Retreatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartz, Melissa, Huang, Gloria S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750011/
https://www.ncbi.nlm.nih.gov/pubmed/26937482
http://dx.doi.org/10.1016/j.gore.2015.12.004
_version_ 1782415360189792256
author Schwartz, Melissa
Huang, Gloria S.
author_facet Schwartz, Melissa
Huang, Gloria S.
author_sort Schwartz, Melissa
collection PubMed
description • Over 90% of granulosa cell tumors have a FOXL2 mutation that contributes to aromatase upregulation. • Chemotherapy has demonstrated limited efficacy in the treatment of granulosa cell tumors. • A patient with recurrent granulosa cell tumor responded briefly to anastrazole treatment. • Retreatment with another aromatase inhibitor letrozole led to a durable response of 24 months.
format Online
Article
Text
id pubmed-4750011
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-47500112016-03-02 Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor Schwartz, Melissa Huang, Gloria S. Gynecol Oncol Rep Case Report • Over 90% of granulosa cell tumors have a FOXL2 mutation that contributes to aromatase upregulation. • Chemotherapy has demonstrated limited efficacy in the treatment of granulosa cell tumors. • A patient with recurrent granulosa cell tumor responded briefly to anastrazole treatment. • Retreatment with another aromatase inhibitor letrozole led to a durable response of 24 months. Elsevier 2015-12-28 /pmc/articles/PMC4750011/ /pubmed/26937482 http://dx.doi.org/10.1016/j.gore.2015.12.004 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Schwartz, Melissa
Huang, Gloria S.
Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor
title Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor
title_full Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor
title_fullStr Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor
title_full_unstemmed Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor
title_short Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor
title_sort retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750011/
https://www.ncbi.nlm.nih.gov/pubmed/26937482
http://dx.doi.org/10.1016/j.gore.2015.12.004
work_keys_str_mv AT schwartzmelissa retreatmentwitharomataseinhibitortherapyinthemanagementofgranulosacelltumor
AT huangglorias retreatmentwitharomataseinhibitortherapyinthemanagementofgranulosacelltumor

Ejemplares similares